

**REMARKS**

Reconsideration is requested.

The teleconference with the Examiner on February 1, 2010 is acknowledged, with appreciation. The present Amendment includes the claim amendments of January 28, 2010 as the status identifier of claim 37 in the Amendment of January 28, 2010 incorrectly identified the amended claims as being "Previously Presented". The undersigned spoke with the Examiner on February 1, 2010 to confirm that submission of the present Amendment, which includes or repeats claim amendments from January 28, 2010 would not be inappropriate.

Claims 20-41 are pending. Claims 23, 26 and 31 have been withdrawn from consideration. The claims have been amended, without prejudice. Support for the amendments may be found throughout the specification. No new matter has been added.

The objection to claim 22 is obviated by the above amendments. Withdrawal of the objection is requested.

The Section 112, second paragraph, rejections of claims 22, 24, 25, 27, 28, 29, 30 and 32-41 are obviated by the above amendments. Withdrawal of the rejections are requested.

The Section 112, first paragraph "enablement", rejection of claims 22, 24, 25, 27-30 and 32-41 is obviated by the above amendments. The claims are submitted to be supported by an enabling disclosure. Withdrawal of the Section 112, first paragraph "enablement", rejection is requested.

LEBLOND et al.  
Appl. No. 10/581,947  
Atty. Ref.: 3665-181  
Supplemental Amendment  
February 1, 2010

The Section 102 rejection of claims 22 and 36 over U.S. Patent No. 5,567,721, is obviated by the above amendments. Withdrawal of the Section 102 rejection is requested in view of, for example, the revision to claim 22 wherein R is optionally another Zn-chelating- group has been removed. Withdrawal of the Section 102 rejection is requested.

The Section 103 rejection of claims 22, 36, 37, 40 and 41 over U.S. Patent No. 5,567,721, is traversed. Reconsideration and withdrawal of the rejection are requested in view of the above and the following.

Clarification is requested regarding the Examiner's reference to and reliance on "the '925 patent" on pages 16-17 of the Office Action dated October 28, 2009 in the event any rejection based on same is maintained. The record does not include citation of a "925 patent" and complete citation of same is not contained in the Office Action of October 28, 2009. The applicants are unable to respond to the Examiner's comments regarding "the '925 patent" without further information.

U.S. Patent No. 5,567,721 discloses carboxylic acids and that these acids can be converted into the corresponding ester or amide. The claimed invention would not have been obvious in view of the cited art. Withdrawal of the Section 103 rejection is requested.

The claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned, preferably by telephone, in the event anything further is required.

LEBLOND et al.  
Appl. No. 10/581,947  
Atty. Ref.: 3665-181  
Supplemental Amendment  
February 1, 2010

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: /B. J. Sadoff/  
B. J. Sadoff  
Reg. No. 36,663

BJS:  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100